Cytokinetics Inc (CYTK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $7.82B
Last updated: Nov 17, 2026 at 4:15 PM ET
Cytokinetics Inc (CYTK) Statistics
Cytokinetics (CYTK) has a market cap of $7.82B and an enterprise value of $8.77B. It kept -686.63% of revenue as net income over the last 12 months. Its share count is up 15.89% from a year earlier.
Total Valuation
Enterprise value is 12.13% above the market cap, as debt exceeds cash.
| Market Cap | $7.82B |
|---|---|
| Enterprise Value | $8.77B |
| Latest price (Nov 17, 2026) | $51.65 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 63.4x. Its year-end P/S ranged from 4.7x to 298.5x from 2016 to 2025.
| P/S Ratio | 63.4x |
|---|---|
| Forward P/S | 47.5x |
Price Statistics
The stock is down 22.26% over 52 weeks and trades 18.34% below its 50-day average.
| Beta (1Y) | 1.07 |
|---|---|
| 52-Week Change | -22.26% |
| 1-Month Change | -17.56% |
| 3-Month Change | -33.56% |
| 6-Month Change | -32.44% |
| 5-Year Change | +80.44% |
| 10-Year Change | +549.38% |
| Total Return (1Y) | -22.26% |
| Total Return (3Y CAGR) | +16.77% |
| Total Return (5Y CAGR) | +4.87% |
| Return vs SPY (1Y) | -33.49% |
| Max Drawdown (1Y) | -40.81% |
| Max Drawdown (3Y) | -72.39% |
| Sharpe Ratio (1Y) | -0.57 |
| Correlation with SPY (1Y) | 0.34 |
| 50-Day Average | $63.25 |
| 200-Day Average | $69.66 |
| 52-Week Range | $52.68 to $88.31 |
| RSI (14 Days) | 30.7 |
| Average Volume (20 Days) | 2.07M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.36x current liabilities.
| Current Ratio | 3.36x |
|---|---|
| Quick Ratio | 3.36x |
| Interest Coverage | -5.06x |
Returns and Efficiency
Return on invested capital is -65.96% over the last 12 months.
| Return on Assets (ROA) | -42.63% |
|---|---|
| Return on Invested Capital (ROIC) | -65.96% |
| Return on Capital Employed (ROCE) | -47.12% |
| ROA (5Y Average) | -44.98% |
| Asset Turnover | 0.07x |
| Receivables Turnover | 3.89x |
Scores
CYTK has an Altman Z-Score of -1.77, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.77 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $113.29M over the last 12 months is up 29.53% from the 12 months before.
| Revenue | $113.29M |
|---|---|
| Revenue Growth (YoY) | +29.53% |
| Gross Profit | $105.60M |
| Operating Income | -$708.24M |
| Pretax Income | -$830.23M |
| Net Income | -$777.89M |
| EBITDA | -$693.31M |
| EBIT | -$693.24M |
| Reported EPS (TTM) | -$6.04 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $203.43M |
|---|---|
| Total Debt | $1.15B |
| Net Debt | $948.07M |
| Net Debt Per Share | $6.82 |
| Working Capital | $833.73M |
| Shareholder Equity | -$321.17M |
| Total Assets | $1.82B |
| Total Liabilities | $2.15B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $16.61M of capital spending, operating cash flow left -$588.58M of free cash flow.
| Operating Cash Flow | -$571.97M |
|---|---|
| Capital Expenditures | $16.61M |
| Free Cash Flow | -$588.58M |
| FCF Per Share | -$4.23 |
| Depreciation and Amortization | $27.10M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -625.15%.
| Gross Margin | 93.21% |
|---|---|
| Operating Margin | -625.15% |
| Pretax Margin | -732.83% |
| Net Margin | -686.63% |
| EBITDA Margin | -611.97% |
| EBIT Margin | -611.91% |
| FCF Margin | -519.53% |
Growth
Revenue fell 2.36% a year over 3 years.
| Revenue Growth (3Y CAGR) | -2.36% |
|---|---|
| Revenue Growth (5Y CAGR) | +9.54% |
Dividends and Yields
CYTK does not pay a dividend. Its free cash flow yield is -8.20%.
| FCF Yield | -8.20% |
|---|---|
| Buyback Yield | -11.65% |
| Shareholder Yield | -11.65% |
Stock Splits
The last split was a 1-for-6 reverse split on Jun 25, 2013.
| Last Split Date | Jun 25, 2013 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:6 |
Peer Position
Against 5 similar companies, CYTK has the 2nd highest P/S.
P/S RatioPeer median 18.8x
ROICPeer median -43.38%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +61.04%
| P/S Ratio | 63.4x vs 18.8x median |
|---|---|
| ROIC | -65.96% vs -43.38% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +29.53% vs +61.04% median |
Analyst Forecast
Consensus estimates put revenue growth at 124.35% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +124.35% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About CYTK
What is CYTK's market cap?
Cytokinetics has a market cap of $7.82B. Its enterprise value, which adds debt and subtracts cash, is $8.77B.
How many shares of CYTK are outstanding?
Cytokinetics has 139.04M shares outstanding. The count is up 15.89% from a year earlier.
Does CYTK pay a dividend?
No. Cytokinetics does not pay a dividend.
How much debt does CYTK have?
Cytokinetics has $1.15B of total debt and $203.43M of cash and equivalents, a net debt position of $948.07M.
CYTK pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors